Two Clinical Readouts Will Decide Whether Intellia Rallies or Reprices in 2026
Intellia (NTLA) sits at a crossroads: one pivotal Phase 3 topline for lonvoguran ziclumeran and progress toward a nexiguran ziclumeran Phase 3 enrollment milestone should drive material re-rating or renewed selling pressure. The company is a high-risk, high-reward biotech with a market cap near $1.3B, negative free cash flow and wide short interest…